Abstract Library

#3631 Are hemicolectomies still indicated in patients with neuroendocrine tumors of the appendix 1-2cm? A retrospective Europe-wide cohort study

Introduction: Awareness of a potential global overtreatment by performing oncological resections for appendiceal neuroendocrine tumors (aNET) 1-2cm is increasing.

Conference:

Presenting Author: Nesti C

Authors: Nesti C, Bräutigam K, Zwahlen M, Perren A,

Keywords: appendix, neuroendocrine tumor, surgery, hemicolectomy, metastasis, survival,

#3427 Updated morphological and immunohistochemical profile of neuroendocrine tumors developed in ovarian teratomas: A large series of a rare disease

Introduction: Ovarian carcinoid tumors are rare, often arising within a mature teratoma. No recent reevaluation of the immunophenotype of these tumors with new markers available has been performed.

Conference:

Presenting Author: Couvelard A

Authors: Leclerc J, Genestie C, Hentic O, Scoazec J, Couvelard A,

Keywords: NET, carcinoid, Ki67, ovarian teratoma, gynecology, pathology,

#3381 Time to reclassify gastric carcinomas of diffuse type to neuroendocrine carcinomas

Introduction: The difference between adeno- and neuroendocrine carcinomas has been disputed for decades. Occurrence of neuroendocrine tumor cells in adenocarcinomas has been recognized, but the distinction between them has been made upon a certain number of tumor cells with a neuroendocrine marker. The number of positive cells depends upon the sensitivity of the method. Carcinogenesis generally results in loss and not gain of function. New gene expression of markers specific for a cell type seldom occurs.

Conference:

Presenting Author: Waldum H

Authors: Waldum H, Mjønes P,

Keywords: adenocarcinoma, neuroendocrine carcinoma, neuroendocrine tumor (NET), classification,

#3188 mTOR pathway inhibitors differently effect proliferation and gene expression in pancreatic and pulmonary NET cell lines

Introduction: The mammalian target of rapamycin (mTOR) is part of the PI3K/Akt/mTOR signalling pathway which has a central role in the oncogenesis of neuroendocrine tumors (NETs). Everolimus (EVE), an mTOR inhibitor, has shown effective in delaying progression of advanced NETs, but with a limited long-term efficacy, possibly due to a compensatory activation of the PI3K/AKT signalling. BYL719, a PI3K inhibitor, was shown to inhibit growth of several NET cell line models.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Mor-Cohen R

Authors: Mor-Cohen R, Braiman N, Tirosh A,

Keywords: NET cell lines, PI3K/Akt/mTOR signalling, Wnt signalling, everolimus, BYL719,

#1115 Cancer Stem Cells in Small Intestine Neuroendocrine Cell Line P-STS: Isolation and Molecular Characterisation

Introduction: Cancer stem cells (CSCs) represent a small subpopulation of tumour cells responsible for invasive tumour growth. Even though the presence of CSCs in neuroendocrine tumours is documented, their role in neuroendocrine tumourigenesis and metastasis is not defined as yet.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kleinegger F, Meier-Allard N, Fuchs R, Hölzl M, Krump C,

Keywords: Cancer stem cells, tumor growth, tumorigenesis & metastasis,